Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELU NASDAQ:CRVO NASDAQ:KLRS NASDAQ:MTVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$2.12-14.7%$2.01$1.00▼$5.22$50.77M0.74370,195 shs254,844 shsCRVOCervoMed$7.70+6.6%$7.46$1.80▼$20.63$66.94M-0.751.34 million shs124,332 shsKLRSKalaris Therapeutics$2.40$0.00$2.28▼$24.15$44.88M0.4838,119 shs29,158 shsMTVAMetaVia$0.67+0.8%$0.70$0.60▼$4.88$13.18M0.21354,356 shs5,907 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity+10.71%+31.22%+41.71%+51.22%-22.26%CRVOCervoMed+1.55%+14.60%+1.40%-23.92%-59.91%KLRSKalaris Therapeutics-8.05%-6.98%-9.09%+239,999,900.00%+239,999,900.00%MTVAMetaVia-5.97%+4.53%-8.82%-9.10%+66,749,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELUCelularity0.0953 of 5 stars0.00.00.00.02.01.70.0CRVOCervoMed3.28 of 5 stars3.45.00.00.02.71.70.6KLRSKalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMTVAMetaVia1.7182 of 5 stars3.50.00.00.01.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELUCelularity 0.00N/AN/AN/ACRVOCervoMed 2.89Moderate Buy$22.57193.33% UpsideKLRSKalaris Therapeutics 0.00N/AN/AN/AMTVAMetaVia 3.00Buy$7.501,014.41% UpsideCurrent Analyst Ratings BreakdownLatest MTVA, KLRS, CRVO, and CELU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/19/2025MTVAMetaViaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.005/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.004/16/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELUCelularity$54.22M0.93N/AN/A$0.37 per share5.72CRVOCervoMed$9.74M6.87N/AN/A$4.50 per share1.71KLRSKalaris TherapeuticsN/AN/AN/AN/A$22.47 per shareN/AMTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELUCelularity-$57.89M-$2.65N/A∞N/A-106.77%-271.88%-42.82%7/21/2025 (Estimated)CRVOCervoMed-$16.29M-$2.18N/AN/AN/A-200.57%-44.07%-40.65%8/8/2025 (Estimated)KLRSKalaris Therapeutics-$58.77MN/A0.00∞N/AN/A-62.08%-54.69%N/AMTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-222.13%-123.85%8/13/2025 (Estimated)Latest MTVA, KLRS, CRVO, and CELU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MTVAMetaVia-$0.32N/AN/AN/AN/AN/A8/8/2025Q2 2025CRVOCervoMed-$0.55N/AN/AN/A$1.45 millionN/A5/14/2025Q1 2025MTVAMetaVia-$0.57-$0.36+$0.21-$0.36N/AN/A5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELUCelularityN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELUCelularity4.070.380.28CRVOCervoMedN/A9.789.78KLRSKalaris TherapeuticsN/A14.3114.31MTVAMetaViaN/A1.551.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELUCelularity19.02%CRVOCervoMed25.15%KLRSKalaris Therapeutics66.05%MTVAMetaVia1.37%Insider OwnershipCompanyInsider OwnershipCELUCelularity22.10%CRVOCervoMed35.40%KLRSKalaris Therapeutics74.99%MTVAMetaVia0.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELUCelularity22023.95 million18.66 millionOptionableCRVOCervoMed48.70 million5.62 millionNot OptionableKLRSKalaris Therapeutics11018.70 million4.68 millionN/AMTVAMetaVia819.59 million19.43 millionN/AMTVA, KLRS, CRVO, and CELU HeadlinesRecent News About These CompaniesMetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...July 10, 2025 | finanznachrichten.deMetaVia doses first patient in 48 mg MAD cohort of its Phase 1 trialJuly 10, 2025 | msn.comMetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated DoseJuly 9, 2025 | prnewswire.comOTC Markets Hosts Virtual Investor Presentation with HH Kim, President and CEO of MetaVia Inc., and David Bautz, PhD, Senior Analyst at Zacks SCRJune 27, 2025 | msn.comMTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…June 24, 2025 | finance.yahoo.comMetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific SessionJune 21, 2025 | prnewswire.comMetaVia to Present at the Life Sciences Virtual Investor Forum June 12thJune 10, 2025 | financialpost.comFMetaVia to Present at the Life Sciences Virtual Investor Forum June 12thJune 10, 2025 | globenewswire.comMetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific SessionsJune 4, 2025 | prnewswire.comMTVA stock touches 52-week low at $0.64 amid market challengesJune 1, 2025 | uk.investing.comMetaVia Faces Nasdaq Delisting Notice for Low Stock PriceMay 30, 2025 | tipranks.comMTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…May 22, 2025 | finance.yahoo.comMetaVia Updates Corporate Presentation on DA-1726 ProgressMay 21, 2025 | tipranks.comMetaVia Inc.: MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 20, 2025 | finanznachrichten.deMetaVia Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comMetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq RulesMay 9, 2025 | prnewswire.comMetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025May 7, 2025 | prnewswire.comMetaVia’s DA-1726 obesity candidate shows efficacy in Part 2 of Phase 1 studyApril 24, 2025 | markets.businessinsider.comMetaVia Advances Pipeline Targeting Obesity, Diabetes, and MASH; Phase 2a Data on DA-1241 to be Presented at EASL 2025April 23, 2025 | theglobeandmail.comMetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025April 23, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTVA, KLRS, CRVO, and CELU Company DescriptionsCelularity NASDAQ:CELU$2.12 -0.37 (-14.72%) As of 12:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.CervoMed NASDAQ:CRVO$7.70 +0.48 (+6.58%) As of 12:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Kalaris Therapeutics NASDAQ:KLRS$2.40 0.00 (0.00%) As of 10:42 AM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.MetaVia NASDAQ:MTVA$0.67 +0.01 (+0.82%) As of 11:58 AM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
